Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELAD in Severe Acute Alcoholic Hepatitis (VTL-308)
NCT02612428Phase 3Terminated
- Sponsor
- Vital Therapies, Inc.
- Start
- Jan 2016
- Primary completion
- Mar 2018
- Modality
- Cell Therapies, Device-based Delivery
- Countries
- 6
01
Overview
A Phase 3 trial of ELAD in acute alcoholic hepatitis (AH), sponsored by Vital Therapies, Inc.. Started Jan 2016; status: terminated.
02
Drugs
ELAD
03
Conditions
acute alcoholic hepatitis (AH)
Beyond the preview
Go deeper on NCT02612428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02612428.